Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
Phishing Ploy Targets COVID-19 Vaccine Distribution Effort
IBM security researchers say they have detected a cyberespionage effort that used targeted phishing emails to try to collect vital information associated with a U.N. initiative for distributing coronavirus vaccine to developing countries.
Stay Home for the Holidays or Get Tested Twice, CDC Urges
The health agency also announced new guidelines that shorten recommended quarantines after close contact with someone infected with coronavirus. Now people can resume normal activity after 10 days, or seven days if they receive a negative test result.
Load More